List of Ongentys drug patents
Ongentys is owned by Neurocrine.
Ongentys contains Opicapone.
Ongentys has a total of 9 drug patents out of which 0 drug patents have expired.
Ongentys was authorised for market use on 24 April, 2020.
Ongentys is available in capsule;oral dosage forms.
Ongentys can be used as adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease, method of treating parkinson's disease, method of inhibiting comt in the periphery; method of treating parkinson's disease; method of reducing o-methylation of l-dopa.
Drug patent challenges can be filed against Ongentys from April, 2024.
The generics of Ongentys are possible to be released after 27 May, 2035.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8907099 | NEUROCRINE | Nitrocatechol derivatives as COMT inhibitors |
May, 2027
(4 years from now) | |
| US8168793 | NEUROCRINE | Nitrocatechol derivatives as COMT inhibitors |
Apr, 2029
(6 years from now) | |
| US9630955 | NEUROCRINE | Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor |
Dec, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9550759 | NEUROCRINE | Nitrocatechol derivatives as COMT inhibitors |
Jul, 2026
(3 years from now) | |
| US9745290 | NEUROCRINE | Dosage regimen for COMT inhibitors |
Oct, 2027
(4 years from now) | |
| US8524746 | NEUROCRINE | Dosage regimen for COMT inhibitors |
Jul, 2029
(6 years from now) | |
| US10071085 | NEUROCRINE | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof |
Mar, 2030
(7 years from now) | |
| US10583130 | NEUROCRINE | Pharmaceutical formulations compromising nitrocatechol derivatives and methods of making thereof |
Mar, 2030
(7 years from now) | |
| US10357468 | NEUROCRINE | Medicaments for slowing Parkinson's disease |
May, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Apr 24, 2025 |
Drugs and Companies using OPICAPONE ingredient
NCE-1 date: April, 2024
Market Authorisation Date: 24 April, 2020
Treatment: Method of inhibiting comt in the periphery; Method of treating parkinson's disease; Method of reducing o-methylation of l-dopa; Adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease
Dosage: CAPSULE;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic